All News

Overall flu activity is at a 10-year high, according to the CDC's most recent influenza surveillance report, while US hospitals are already overwhelmed.

Your daily dose of clinical news you may have missed.

Teplizumab, an anti-CD3 monoclonal antibody, delayed the median onset of stage 3 T1D by approximately 2 years compared to placebo in a pivotal clinical trial.

Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.

The low rate of stroke prevention with oral anticoagulation in patients with atrial fibrillation is cause for significant concern, say investigators.

A preliminary assessment from the FDA suggests certain naloxone products may be safely used without a prescription to prevent opioid overdose deaths.

A guideline topline of the CDC's 2022 clinical guidance for prescribing opioids for pain in adults.

Obesity physician-scientist Andres Acosta, MD, PhD, reviews findings from recent studies he led that suggest true potential for phenotype-focused weight loss intervention.

While 60% of US psychologists have no openings for new patients, demand for treatment continues to rise, especially among adolescents and health care workers.

Analysis of women who did not have high blood pressure while pregnant found that 1 in 10 were diagnosed with hypertension in the year after delivery.

Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

Your daily dose of clinical news you may have missed.

A vaccine against fentanyl could stop the intense euphoria the drug creates and also block dangerous physiologic responses like respiratory depression, a new study suggests.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.

Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.

Your daily dose of clinical news you may have missed.